• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医院急诊科中静脉注射磷苯妥英钠(赛瑞比克斯)与静脉注射苯妥英钠(大仑丁)的药物经济学评价

A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments.

作者信息

Marchetti A, Magar R, Fischer J, Sloan E, Fischer P

机构信息

Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, USA.

出版信息

Clin Ther. 1996 Sep-Oct;18(5):953-66. doi: 10.1016/s0149-2918(96)80051-8.

DOI:10.1016/s0149-2918(96)80051-8
PMID:8930434
Abstract

The cost of emergency department services has become a major concern for patients, providers, and payers. Solid economic information is needed to provide a rationale for the selection of therapeutic options and the provision of care that is both clinically and financially prudent. To assess the full cost of care for patients with seizures who are treated in an acute care setting, a modified activity-based cost-accounting model was developed. The model was populated with data from a double-masked, parallel-group, single-dose, multicenter clinical trial designed to investigate the safety and tolerability of phenytoin (Dilantin) and fosphenytoin (Cerebyx) given intravenously in equivalent loading doses according to established recommendations. A total of 52 patients were enrolled in the trial; 13 were given phenytoin and 39 were given fosphenytoin. Salaries and benefits of emergency medical services personnel, drug acquisition costs, and direct and indirect overhead expenditures common to a large hospital emergency department comprised the total costs to treat enrolled patients and manage adverse events. The average cost to treat patients with fosphenytoin was lower than the cost to treat similar patients with phenytoin based on the frequency of adverse events associated with each comparator and the resources (human and material) consumed in the management of those events.

摘要

急诊科服务的成本已成为患者、医疗服务提供者和支付方主要关注的问题。需要可靠的经济信息,以便为选择治疗方案以及提供临床和财务上都审慎的护理提供依据。为了评估在急性护理环境中接受治疗的癫痫患者的全部护理成本,开发了一种改良的基于活动的成本核算模型。该模型的数据来自一项双盲、平行组、单剂量、多中心临床试验,该试验旨在根据既定建议,研究静脉注射等效负荷剂量的苯妥英钠(大仑丁)和磷苯妥英钠(开浦兰)的安全性和耐受性。共有52名患者参加了该试验;13名患者接受了苯妥英钠治疗,39名患者接受了磷苯妥英钠治疗。大型医院急诊科急救医疗服务人员的薪资和福利、药品采购成本以及直接和间接间接费用支出构成了治疗登记患者和处理不良事件的总成本。基于与每个对照药物相关的不良事件发生频率以及处理这些事件所消耗的资源(人力和物力),使用磷苯妥英钠治疗患者的平均成本低于使用苯妥英钠治疗类似患者的成本。

相似文献

1
A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments.医院急诊科中静脉注射磷苯妥英钠(赛瑞比克斯)与静脉注射苯妥英钠(大仑丁)的药物经济学评价
Clin Ther. 1996 Sep-Oct;18(5):953-66. doi: 10.1016/s0149-2918(96)80051-8.
2
Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department.急诊科口服苯妥英钠、静脉注射苯妥英钠及静脉注射磷苯妥英钠的成本效益分析
Ann Emerg Med. 2004 Mar;43(3):386-97. doi: 10.1016/j.annemergmed.2003.10.011.
3
Phenytoin and fosphenytoin: a model of cost and clinical outcomes.苯妥英钠和磷苯妥英钠:成本与临床结果模型
Pharmacotherapy. 1999 Jul;19(7):844-53. doi: 10.1592/phco.19.10.844.31556.
4
Fosphenytoin farewell?磷苯妥英要告别了?
Ann Emerg Med. 2004 Mar;43(3):398-400. doi: 10.1016/j.annemergmed.2003.11.007.
5
Fosphenytoin. Pharmacoeconomic implications of therapy.磷苯妥英钠。治疗的药物经济学影响。
Pharmacoeconomics. 1998 Dec;14(6):685-90. doi: 10.2165/00019053-199814060-00008.
6
Pharmacoeconomic considerations in treatment options for acute seizures.
J Child Neurol. 1998 Oct;13 Suppl 1:S27-9; discussion S30-2. doi: 10.1177/0883073898013001081.
7
Inappropriate fosphenytoin use in the ED.急诊科中磷苯妥英的不当使用。
Am J Emerg Med. 2001 Jul;19(4):293-4. doi: 10.1053/ajem.2001.24471.
8
Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.急诊科苯妥英钠和磷苯妥英钠的成本最小化分析。
Pharmacotherapy. 2000 Aug;20(8):908-16. doi: 10.1592/phco.20.11.908.35269.
9
The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.磷苯妥英在神经外科患者中肌肉注射和静脉注射后的安全性、耐受性及药代动力学。
Pharmacotherapy. 1996 Jul-Aug;16(4):638-45.
10
Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED.肌内注射苯妥英钠与静脉注射苯妥英钠在急诊科的负荷剂量比较。
Am J Emerg Med. 2011 Nov;29(9):983-8. doi: 10.1016/j.ajem.2010.05.005. Epub 2010 Aug 3.

引用本文的文献

1
Cardiovascular adverse effects of phenytoin.苯妥英钠的心血管不良反应。
J Neurol. 2016 May;263(5):861-870. doi: 10.1007/s00415-015-7967-1. Epub 2015 Dec 8.
2
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes.磷苯妥英钠治疗癫痫持续状态:基于证据对其临床和经济结果的评估
Core Evid. 2005;1(1):65-75. Epub 2005 Mar 31.
3
Prescribing antiepileptic drugs: should patients be switched on the basis of cost?抗癫痫药物的处方:患者是否应根据成本进行换药?
CNS Drugs. 2004;18(10):617-28. doi: 10.2165/00023210-200418100-00001.
4
Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.磷苯妥英:癫痫急性治疗中的临床药代动力学及比较优势
Clin Pharmacokinet. 2003;42(1):33-58. doi: 10.2165/00003088-200342010-00002.
5
Convulsive Status Epilepticus.
Curr Treat Options Neurol. 1999 Sep;1(4):359-369. doi: 10.1007/s11940-999-0025-5.
6
Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.癫痫持续状态患者使用磷苯妥英和苯妥英:耐受性改善与成本增加
Drug Saf. 2000 Jun;22(6):459-66. doi: 10.2165/00002018-200022060-00004.
7
Fosphenytoin. Pharmacoeconomic implications of therapy.磷苯妥英钠。治疗的药物经济学影响。
Pharmacoeconomics. 1998 Dec;14(6):685-90. doi: 10.2165/00019053-199814060-00008.